TLDR: Gene therapy for hearing loss is real and working — but only for specific types of genetic hearing loss right now. The biggest breakthrough has been with OTOF gene mutations, where a single injection into the inner ear has restored hearing in children and adults in clinical trials. Most patients with age-related loss, noise damage, or non-genetic causes cannot access this yet. Hearing aids and cochlear implants remain the most effective tools for most people with hearing loss in Singapore today.
If you’ve seen the videos circulating in 2025 and 2026 of children hearing sound for the first time after a gene therapy injection, it’s hard not to feel something. A child reacting to their mother’s voice. An adult describing sounds they had never heard before. These are real. They happened. And they represent a genuine turning point in how certain types of deafness can be treated.
But there’s a lot of noise around gene therapy for hearing loss — exaggerated claims, misunderstood findings, and people asking whether this means hearing aids and cochlear implants are about to become obsolete. They’re not, and understanding why requires understanding what gene therapy actually does and who it currently helps.
At The Hearing Centre in Singapore, our audiologists get questions about this regularly. Here’s an honest, up-to-date picture of where gene therapy for hearing loss actually stands.
What Is Gene Therapy for Hearing Loss?
Gene therapy delivers a working copy of a gene directly into cells that need it. In the case of hearing loss, the target is usually the hair cells inside the cochlea — the tiny sensory cells that convert sound vibrations into electrical signals the brain reads as sound.
When a person is born with a mutation in a specific gene, those hair cells either don’t develop properly or fail early in life. The result is congenital deafness or severe hearing impairment from birth or early childhood. Gene therapy delivers a corrected copy of the faulty gene into the inner ear using a specially engineered harmless virus called an adeno-associated virus (AAV). The virus carries the genetic instruction into the cells, the cells begin producing the protein they were missing, and hearing function can return.
This isn’t science fiction. It’s happening in clinical trials right now, with results published in peer-reviewed journals including Nature.
The Breakthrough: OTOF Gene Therapy
The biggest results so far involve a gene called OTOF. Mutations in the OTOF gene cause a condition called DFNB9 — a form of genetic deafness where the hair cells are structurally present but functionally broken. They can’t send signals to the auditory nerve because the protein they need, otoferlin, is missing or defective.
This is called auditory neuropathy. Children with DFNB9 are born profoundly deaf or severely hearing impaired. Conventional hearing aids don’t help because the hair cells aren’t producing the right signals regardless of how much sound is amplified. Cochlear implants have been used, but they bypass the hair cells entirely rather than fixing them.
In April 2026, researchers from Mass General Brigham, Harvard Medical School, and Fudan University published results in Nature from the largest gene therapy trial for inherited hearing loss to date. 42 participants across eight sites, ranging from infants to young adults, received a single injection of gene therapy into the inner ear through the round window membrane at the base of the cochlea. Most began regaining hearing within weeks. 90% of participants still had significantly improved hearing, with half reaching normal hearing levels. One participant’s father was quoted saying the results were better than his own hearing.
An earlier 2026 study from Karolinska Institutet and Chinese collaborators treated ten patients and saw hearing improve in every single one. Average detectable sound level improved from 106 decibels to 52 decibels. Children aged five to eight showed the most dramatic improvements.
How the Injection Works
The procedure itself is relatively straightforward compared to what it achieves.
A single injection is given through a thin membrane at the base of the cochlea called the round window. The AAV virus carrying the working OTOF gene enters the fluid of the cochlea and finds its way to the hair cells. Inside those cells, it delivers the genetic instructions. The cells begin producing otoferlin — the protein they were missing. With otoferlin present, the hair cells can do their job: convert sound vibration into signals the auditory nerve carries to the brain.
The whole process takes weeks to months to show results, with most patients noticing changes within the first month and continuing improvement over six months or more.
Who Gene Therapy for Hearing Loss Currently Helps
This is the most important thing to understand clearly.
Right now, gene therapy for hearing loss primarily helps people with OTOF gene mutations causing DFNB9-type congenital deafness. This is a specific, relatively uncommon cause of hearing loss. It represents a small percentage of all people with hearing impairment.
Current candidates for OTOF gene therapy:
- Children and adults born profoundly deaf or severely hearing impaired due to OTOF mutations
- People with confirmed DFNB9 diagnosis through genetic testing
- Patients with functioning cochlear anatomy capable of receiving the injection
- Cases where genetic testing has confirmed the specific mutation gene therapy targets
Who gene therapy does NOT currently help:
- Age-related hearing loss (presbycusis) — not genetic in the same targetable way
- Noise-induced hearing loss — hair cell damage rather than a gene mutation
- Most other forms of sensorineural hearing loss — different genes, different mechanisms
- Conductive hearing loss — a mechanical issue, not a gene problem
Where Singapore Fits In
You can’t walk into a clinic in Singapore and get this treatment today — it’s simply not available here yet. The trials behind these results took place in China, Europe, and the US, and while a real approved treatment now exists in the US, that approval hasn’t extended to Singapore or most other countries. More markets are expected to follow as regulatory reviews continue, but for now, this remains something to watch rather than something to book. And even where it is available, it isn’t the go-to solution most people with hearing loss will turn to — it’s a narrow, specific treatment for a rare genetic cause, not a mainstream option like hearing aids or cochlear implants .
What Singapore does have is excellent newborn hearing screening, genetic testing capability, and comprehensive hearing care including hearing aids and cochlear implants. For families in Singapore whose children have been identified with newborn hearing test results suggesting congenital hearing loss, genetic testing is increasingly part of the diagnostic pathway. Knowing the specific genetic cause opens the door to understanding whether gene therapy may be relevant as it becomes accessible.
The Hearing Centre works with ENT specialists and the broader Singapore medical community, and as gene therapy becomes clinically available in the region, the pathway from genetic diagnosis to treatment will become clearer.
Gene Therapy vs Cochlear Implant: What’s the Difference?
People often ask this. They’re not the same thing, and they don’t do the same job.
Gene Therapy | Cochlear Implant | |
What it does | Repairs the biological function of hair cells | Bypasses hair cells, stimulates nerve directly |
Who it helps | Specific genetic mutations (currently mainly OTOF) | Severe to profound sensorineural hearing loss, any cause |
Surgery required | Injection into inner ear | Surgical implant under general anaesthetic |
Currently available | Clinical trials, limited regulatory approval | Widely available in Singapore |
Long-term results | Up to 2.5 years confirmed so far | Decades of evidence |
Restores natural hearing | Potentially, in some cases | No — electrical simulation of sound |
A cochlear implant remains the most proven and widely available treatment for severe to profound hearing loss in Singapore right now. For children with DFNB9 who might previously have received a cochlear implant, gene therapy is now a serious alternative — one that restores the hair cells’ natural function rather than replacing them with electronics.
Gene Therapy vs Hearing Aids
Hearing aids amplify sound for ears that can still process it. Gene therapy repairs the biological mechanism that processes sound in the first place. They’re not competing — they serve completely different problems.
For the vast majority of people using hearing aids Singapore today — those with age-related loss, noise damage, or non-OTOF forms of hearing loss — gene therapy is not a current alternative. Hearing aids from Phonak, Signia, Oticon, ReSound, Starkey, and Widex remain the most effective management available, and the technology in these devices has advanced significantly in the past five years.
People sometimes hear about gene therapy breakthroughs and wonder whether they should hold off on getting hearing aids. They shouldn’t. Age-related and noise-induced hearing loss progresses. Untreated hearing loss is linked to cognitive decline, social withdrawal, and reduced quality of life. The right time to address hearing loss is now, with the tools that exist now.
What’s Coming Next
The OTOF result is genuinely exciting partly because of what it suggests is possible beyond OTOF itself. Researchers are already working on:
GJB2 mutations — GJB2 is the most common cause of inherited hearing loss globally. It affects far more people than OTOF. A gene therapy approach for GJB2-related deafness is actively being developed, with early research underway.
Hair cell regeneration — most age-related and noise-induced hearing loss involves permanent hair cell death. Mammals can’t regenerate cochlear hair cells after birth — but birds and fish can. Research is ongoing into whether genes responsible for hair cell regeneration in other species can be switched on in the human cochlea. The Hearing Restoration Project has identified specific gene “switches” that activate exclusively in the ear’s supporting cells, which is a significant step toward this.
Gene editing — CRISPR-based approaches that edit the existing faulty gene in place rather than delivering a separate copy are also in development. These could potentially address dominant gene mutations (where one faulty copy of a gene causes problems even when the other is normal) that gene addition can’t easily fix.
Combination approaches — some researchers are exploring gene therapy alongside cochlear implants, where the implant handles immediate hearing needs while gene therapy works to restore underlying hair cell function over time.
None of these are available as clinical treatments yet. Most are years away from routine clinical use. But the pace of progress has accelerated significantly. Gene therapy for hearing loss moved from theoretical concept to published clinical results faster than most expected.
What to Do If You Think Genetic Hearing Loss Might Be Relevant to You
If you or your child have been diagnosed with congenital hearing loss, finding out the genetic cause matters now more than ever. With gene therapy for hearing loss entering clinical use for specific mutations, knowing whether OTOF or another targetable gene is involved determines whether this is a relevant conversation.
At The Hearing Centre, audiologists work with patients and families from the point of diagnosis — newborn hearing screening, comprehensive hearing assessments, and referral to the appropriate specialists including ENT doctors and genetic services. If genetic testing has already been done and you want to understand what those results mean for current and future treatment options, that’s a conversation worth having.
For the vast majority of patients with hearing loss today, the conversation is about hearing aids and cochlear implants. But for a growing number — particularly families with children born with specific genetic forms of deafness — gene therapy for hearing loss is entering that conversation too.
Book a hearing test at The Hearing Centre as the first step. Understanding the type and degree of hearing loss, and whether genetic testing is appropriate, is how any treatment pathway starts.
Frequently Asked Questions
A treatment that delivers a working copy of a faulty gene directly into the inner ear using a harmless virus. In people with specific genetic mutations, this can restore the function of hair cells in the cochlea, allowing them to process sound normally.
For specific genetic causes — particularly OTOF mutations causing DFNB9 — yes. Clinical trials published in Nature in 2026 showed hearing improvement in the majority of participants, with results lasting up to 2.5 years. Children showed the most dramatic responses.
People with confirmed OTOF gene mutations causing congenital deafness. This is a specific, relatively uncommon form of inherited hearing loss. Most people with age-related, noise-induced, or non-OTOF genetic hearing loss are not yet candidates.
Not currently. Age-related hearing loss involves a different mechanism from the genetic mutations that gene therapy targets. Research into hair cell regeneration may eventually change this, but it’s years away from clinical application.
Not as a routine clinical treatment yet. Trials took place in China, Sweden, and the US. Regulatory approval is underway in some countries. Singapore has excellent diagnostic services including genetic testing, which is the first step in identifying whether gene therapy will be relevant when it becomes accessible.
A cochlear implant bypasses damaged hair cells and stimulates the auditory nerve directly with electrical signals. Gene therapy aims to repair the biological function of the hair cells themselves. They work on completely different principles and suit different situations.
No. Gene therapy is currently relevant only for specific rare genetic forms of hearing loss. For the vast majority of people with age-related or noise-induced hearing loss, hearing aids from brands like Phonak, Signia, Oticon, ReSound, and Starkey remain the most effective treatment available. Delaying management while waiting for a treatment that may not apply to your type of loss causes real harm.
A single injection through a membrane at the base of the cochlea called the round window. A harmless modified virus carries the genetic instruction into the hair cells of the cochlea, where it begins producing the protein those cells were missing.
GJB2 — the most common cause of inherited hearing loss globally — is the next major target. Research into hair cell regeneration for age-related and noise-induced loss is also ongoing, though much further from clinical use.
